Table 2 hrHPV prevalence, by self-reported HIV infection status, among women from two rural districts of Uganda participating in a community-based study of cervical cancer screening
hrHPV Type Detected | HIV-infectedc Participants (N = 160) % (95% CI) | HIV-uninfected Participants (N = 1507) % (95% CI) | HIV-untested Participants (N = 225) % (95% CI) | All Participants (N = 1892) % (95% CI) |
|---|---|---|---|---|
Any hrHPV | 40% (32 to 48%) | 19% (17 to 21%) | 17% (12 to 22%) | 21% (19 to 23%) |
At least one of HPV-16, 18 and 45a | 11% (6.3 to 16%) | 4.0% (3.1 to 5.2%) | 4.0% (1.8 to 7.5%) | 4.6% (3.7 to 5.6%) |
HPV-16a, b | 4.4% (1.8 to 8.8%) | 2.7% (1.9 to 3.6%) | 2.2% (0.7 to 5.1%) | 2.7% (2.1 to 3.6%) |
HPV-18 and/or 45a, b | 6.9% (3.5 to 12%) | 1.5% (0.9 to 2.2% | 1.8% (0.5 to 4.5%) | 1.8% (1.3 to 2.6%) |
At least one of HPV-31, 33, 35, 39, 51, 52, 56, 58, 59, 66 and 68 but without 16, 18 and 45 | 29% (22 to 36%) | 15% (13 to 17%) | 13% (8.8 to 18%) | 16% (14 to 18%) |